Press Releases

Momentum Stocks: Whiting Petroleum Corporation (WLL), Oclaro, Inc. (OCLR), Delcath Systems, Inc. (DCTH)

earningswp17

Whiting Petroleum Corporation (WLL) retreated with the stock falling -1.4% or $-0.16 to close at $11.28 on active trading volume of 9.18M compared its three months average trading volume of 16.95M. The Denver Colorado 80290 based company operating under the Oil & Gas Drilling & Exploration industry has been trending up for the last 52 weeks, with the shares price now 110.06% up for the period and down by -6.16% so far this year. With price target of $14.21 and a 236.72% rebound from 52-week low, Whiting Petroleum Corporation has plenty of upside potential, making it a hold with a view buy.

Whiting Petroleum Corporation, an independent oil and gas company, engages in the acquisition, exploration, development, and production of crude oil, natural gas liquids, and natural gas in the Rocky Mountains and Permian Basin regions of the United States. It sells oil and gas to end users, marketers, and other purchasers. As of December 31, 2015, the company had total estimated proved reserves of 820.6 million barrels of oil equivalent; and interests in 3,177 net productive wells on approximately 593,900 net developed acres. Whiting Petroleum Corporation was founded in 1980 and is based in Denver, Colorado.

Oclaro, Inc. (OCLR) had a active trading with around 9.02M shares changing hands compared to its three month average trading volume of 6.41M. The stock traded between $10.47 and $10.91 before closing at the price of $10.8 with -0.64% change on the day. The San Jose California 95131 based company is currently trading 179.79% above its 52 week low of $3.86 and -1.46% below its 52 week high of $10.96. Both the RSI indicator and target price of  and $14.28 respectively, lead us to believe that it could rise over the coming weeks.

Oclaro, Inc. designs, manufactures, and markets lasers and optical components, modules, and subsystems for the optical communications, industrial, and consumer laser markets worldwide. The company’s products generate, detect, combine, and separate light signals in optical communications networks. It offers client side transceivers, including pluggable transceivers; line side transceivers; tunable laser transmitters, such as discrete lasers and co-packaged laser modulators; lithium niobate modulators to manipulate the phase or the amplitude of an optical signal; transponder modules for transmitter and receiver functions; and discrete lasers and receivers for metro and long-haul applications. The company markets its products through direct sales force, as well as through sales representatives and resellers. It serves network equipment manufacturers of telecommunications and datacom systems, and hyperscale data center operators. The company was formerly known as Bookham, Inc. and changed its name to Oclaro, Inc. in April 2009. Oclaro, Inc. was founded in 1988 and is headquartered in San Jose, California.

Delcath Systems, Inc. (DCTH) saw its value decrease by -21.2% as the stock dropped $-0.04 to finish the day at a closing price of $0.17. The stock was higher in trading and has fluctuated between $0.13-$6.848 per share for the past year. The shares, which traded within a range of $0.131 to $0.205 during the day, are down by -91.71% in the past three months and down by -95.83% over the past six months. It is currently trading -47.96% below its 20 day moving average and -80.07% below its 50 day moving average. Analysts believe the company can continue to increase in value to reach at $16 a share over the next twelve months. The current relative strength index (RSI) reading is 19.27.The technical indicator lead us to believe the stock will reverse recent losses any time soon.

Delcath Systems, Inc. operates as a specialty pharmaceutical and medical device company focusing on cancers of the liver. The company is developing its proprietary product-Melphalan Hydrochloride for injection for use with the Delcath Hepatic Delivery System; and markets melphalan hydrochloride as a device under the trade name Delcath Hepatic CHEMOSAT Delivery System for Melphalan in Europe. Its primary focus is on the execution of its clinical development program in ocular melanoma liver metastases, intrahepatic cholangiocarcinoma, hepatocellular carcinoma, and certain other cancers that are metastatic to the liver. Delcath Systems, Inc. was founded in 1988 and is headquartered in New York, New York.

 

Previous ArticleNext Article

Leave a Reply

Your email address will not be published. Required fields are marked *